HCP engagement solutions – being present isn’t enough
Pf Media Magazine
by Emma Morriss
6d ago
Have you invested in digital engagement of HCPs? Are you preparing for the future? When it comes to engaging healthcare professionals online, being present isn’t enough. You need strategic engagement solutions to meet their needs across multiple channels. The pharmaceutical industry has significantly increased its digital engagement presence – websites, education portals, virtual events, podcasts, there’s no shortage of content available to share with customers and support their education and patients. But what may have been a scattergun approach, activity by activity and need by nee ..read more
Visit website
AI tool set to make drug discovery 100 times faster
Pf Media Magazine
by Joanna Harvey
6d ago
bioXcelerate, a health data science division of Optima Partners Limited, have launched a new AI tool, which is set to accelerate the process for identifying and developing new drugs. The tool, known as PleioGraph, can analyse complex medical data 100 times faster than existing state-of-the-art methods, used to detect biological networks which explain disease risk and inform drug discovery. The technology uses bioXcelerate’s own machine learning algorithms to sweep huge amounts of biological data to help drug developers identify the genes, proteins and cells that interact with each other to cau ..read more
Visit website
Roquette acquires IFF Pharma Solutions
Pf Media Magazine
by Joanna Harvey
6d ago
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, has acquired IFF Pharma Solutions, a worldwide producer of excipients for oral dosage solutions, to reinforce its position as a major partner to the pharmaceutical industry. The combination of the two complementary businesses will rebalance the company’s portfolio around the two pillars of health and nutrition. It will expand its pharma product range and significantly accelerate Roquette’s growth. The acquisition enhances Roquette’s US footprint, and significantly expands its industry-leading formulation capabi ..read more
Visit website
Almirall expands pipeline to rare dermatological diseases
Pharmafield Magazine
by Joanna Harvey
2w ago
Almirall has signed a licensing agreement with Eloxx Pharmaceuticals to acquire ZKN-013 – the first asset in Almirall’s pipeline focused on rare diseases. Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases. ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases. The drug candidate is expected to shortly enter into Phase I develop ..read more
Visit website
SMC accepts AbbVie’s new Parkinson’s drug within NHS Scotland
Pharmafield Magazine
by Joanna Harvey
2w ago
The Scottish Medicines Consortium (SMC) has accepted AbbVie’s new Produodopa® (foslevodopa-foscarbidopa) for restricted use within NHS Scotland for the treatment of advanced levodopa-responsive Parkinson’s disease. The SMC has restricted its use to patients with advanced Parkinson’s disease who are not eligible for deep brain stimulation (DBS). Foslevodopa-foscarbidopa offers an additional treatment choice in the therapeutic class of dopa and dopaderivatives for this indication. Another medicine within this therapeutic class has been accepted via the orphan medicine process for this indication ..read more
Visit website
Pf Awards 2024 Winners Announced
Pharmafield Magazine
by Joanna Harvey
2w ago
The Pf Awards 2024 winners were announced on Thursday 7 March, celebrating the 24th year of recognising outstanding achievements in the pharmaceutical industry.   Paul Sinha, known famously as The Sinnerman on ITV’s The Chase, bought a wealth of humour to the ceremony, which this year was in partnership with Parkinsons UK.   The evening’s celebrations were opened by our 2023 Outstanding Individual Performer Winners, Adele Marshall and Sarah Valente-Smith, from MSD. The duo touched on how their win boosted their confidence and reinforced that living their values and challeng ..read more
Visit website
Akari Therapeutics merge with Peak Bio
Pharmafield Magazine
by Joanna Harvey
2w ago
Akari Therapeutics have merged with Peak Bio, with an expanded pipeline that contains multiple compelling assets, spanning early and late development stages. An assessment of the pipeline is planned, including program prioritisation, updated timelines, near-term value creation opportunities, and other considerations. The combined entity will operate as Akari Therapeutics, Plc. Key highlights of the merger include a robust ADC toolkit with novel payload and linker technologies, multiple compelling assets spanning early and late stages, strategic focus to emphasise business development and licen ..read more
Visit website
NICE recommends first immunotherapy treatment for endometrial cancer patients
Pharmafield Magazine
by Joanna Harvey
2w ago
Jemperli▼ (dostarlimab) has become the first immunotherapy treatment to receive recommendation for use from the National Institute for Health and Care Excellence (NICE), in eligible endometrial cancer patients in a first line setting. Following the positive recommendation, approximately 580 patients in England, Wales and Northern Ireland could be eligible for treatment with dostarlimab1. This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instabi ..read more
Visit website
Ipsen appoints Ioana Parsons as UK and Ireland General Manager
Pharmafield Magazine
by Emma Cooper
3w ago
Ipsen has announced the appointment of Ioana Parsons as General Manager of the company’s U.K. & Ireland affiliate. Ioana joins from Ipsen Poland, where she has been General Manager for the past three years. As well as becoming U.K. & I General Manager, Ioana will act as Head of Site for Ipsen’s U.K. Global Hub. Ioana has a wealth of experience working in the Life Sciences industry including local, regional and global roles at major pharmaceutical companies. In addition to this, she has worked as a consultant at McKinsey & Company in London, where she led large scale strategy and co ..read more
Visit website
NICE recommends Janssen’s rare disease treatment
Pharmafield Magazine
by Emma Cooper
3w ago
The National Institute for Health and Care Excellence (NICE) has recommended Janssen’s DARZALEX® (daratumumab) plus VELCADE® (bortezomib), cyclophosphamide and dexamethasone (DVCd) as an option for newly diagnosed systemic amyloid light-chain (AL) amyloidosis.1 DVCd is recommended subject to a commercial agreement, and only if daratumumab is stopped after 24 cycles of treatment, or earlier if the condition progresses.1 This positive decision follows an extensive appraisal process including an appeal against the original guidance from NICE in November 2022, and means that eligible individuals t ..read more
Visit website

Follow Pf Media Magazine on FeedSpot

Continue with Google
Continue with Apple
OR